GSTM1 and anemia (phenotype): Another study in 104 ovarian cancer patients that received paclitaxel and carboplatin found carriers of a homozygous GSTM1 gene deletion were less likely to develop grade 1-4 thrombocytopenia (OR = 0.13; 95% CI: 0.03–0.62; p = 0.005) and grade 2-4 anemia (OR = 0.29; 95% CI: 0.13–0.66; p = 0.003) than those of functional GSTM1 variants (Khrunin et al., 2010).